Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

類似資料

• Treatment of Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor Results in Improved Event-Free Survival
  著者:: Borthakur, Gautam, 等
  出版事項: (2008)
• Gemtuzumab Ozogamicin: Time to Resurrect?
  著者:: Ravandi, Farhad, 等
  出版事項: (2012)
• Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast-Phase Chronic Myeloid Leukemia
  著者:: Jabbour, Elias, 等
  出版事項: (2012)
• A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin in Patients with Relapsed or Refractory Acute Myeloid Leukemia
  著者:: Tsimberidou, Apostolia-Maria, 等
  出版事項: (2014)
• A phase II Study of Decitabine and Gemtuzumab Ozogamicin in Newly Diagnosed and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
  著者:: Daver, Naval, 等
  出版事項: (2015)